Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 17/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1579287 | 0.84 | CXCR2 (0.42) | CCR6CXCR1CXCR2ALDH1A1 | |
| SCHEMBL17309435 | 0.82 | SMN1; SMN2 (0.44) | CCR6ALDH1A1 | |
| SCHEMBL20721264 | 0.82 | CCR6 (0.47) | CCR6CXCR1CXCR2ALDH1A1 | |
| SCHEMBL14227577 | 0.80 | ALDH1A1 (0.40) | CXCR1CXCR2ALDH1A1 | |
| SCHEMBL13205479 | 0.79 | CXCR2 (0.39) | CCR6CXCR1CXCR2ALDH1A1 | |
| SCHEMBL5711823 | 0.78 | CCR6 (0.39) | CCR6CXCR1CXCR2 | |
| SCHEMBL4604015 | 0.78 | CXCR2 (0.47) | CXCR1CXCR2ALDH1A1 | |
| SCHEMBL1579037 | 0.77 | ALDH1A1 (0.37) | CCR6CXCR1CXCR2ALDH1A1 | |
| SCHEMBL22606471 | 0.77 | CXCR2 (0.48) | CCR6CXCR1CXCR2ALDH1A1 | |
| SCHEMBL12779597 | 0.77 | CCR6 (0.57) | CCR6CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3668832-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | Allergan, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20030050298-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-03-13 | — | — | US | disclosed |
| EP-1272175-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
| EP-1261329-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002079122-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001072960-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001068033-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CCR6 197/4885CXCR1 156/4885CXCR2 303/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | CCR6 197/4885CXCR1 156/4885CXCR2 303/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CCR6 197/4885CXCR1 156/4885CXCR2 303/4885 |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | CCR6 20/4885CXCR1 2/4885CXCR2 1/4885 |
| US-20030050298-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CCR6 30/4885CXCR1 12/4885CXCR2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.